T’d up, bro.

In an attempt to even out the playing field across classes A-E, this single-arm phase two study enrolled 20 patients with metastatic or advanced recurrent soft tissue sarcoma and treated them with pembrolizumab in conjunction with intratumoral injections of T-VEC, a modified herpes virus designed to lyse tumor to release antigens. An objective response occurred in 7 of 20 enrollees, which isn’t too shabby considering the median number of prior systemic therapies was 3. | Kelly, JAMA Oncol 2020